C A Melfi

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression
    C A Melfi
    Health Outcomes Evaluation Group, Eli Lilly and Co, Indianapolis, Ind 46285, USA
    Arch Gen Psychiatry 55:1128-32. 1998
  2. ncbi Use of claims data for research on treatment and outcomes of depression care
    C A Melfi
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Med Care 37:AS77-80. 1999
  3. ncbi Racial variation in antidepressant treatment in a Medicaid population
    C A Melfi
    Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 61:16-21. 2000
  4. ncbi Using databases for studying and comparing health care costs and resource use
    C A Melfi
    Eli Lilly and Company, Department of Medicine, Indiana University, Indianapolis, IN, USA
    Pharmacoepidemiol Drug Saf 10:399-402. 2001
  5. ncbi Effect of mental health specialty care on antidepressant length of therapy
    T W Croghan
    Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Med Care 37:AS20-3. 1999
  6. ncbi Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy
    R L Obenchain
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Pharmacoeconomics 11:464-72. 1997
  7. ncbi Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals
    T W Croghan
    Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Adm Policy Ment Health 27:183-95. 2000

Collaborators

Detail Information

Publications7

  1. ncbi The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression
    C A Melfi
    Health Outcomes Evaluation Group, Eli Lilly and Co, Indianapolis, Ind 46285, USA
    Arch Gen Psychiatry 55:1128-32. 1998
    ..In this article, we test whether adherence to these recommendations reduces the likelihood of relapse or recurrence in a Medicaid population...
  2. ncbi Use of claims data for research on treatment and outcomes of depression care
    C A Melfi
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Med Care 37:AS77-80. 1999
    ..Data sources such as medical insurance claims are increasingly used in outcomes research. In this report, we present opportunities and limitations associated with the use of such data for outcomes research in the area of depression...
  3. ncbi Racial variation in antidepressant treatment in a Medicaid population
    C A Melfi
    Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 61:16-21. 2000
    ..With this study, we examine racial differences in the antidepressant usage in a Medicaid population...
  4. ncbi Using databases for studying and comparing health care costs and resource use
    C A Melfi
    Eli Lilly and Company, Department of Medicine, Indiana University, Indianapolis, IN, USA
    Pharmacoepidemiol Drug Saf 10:399-402. 2001
    ..Still, databases represent a rich opportunity to conduct research in health care costs and resource use, and much can be learned using databases...
  5. ncbi Effect of mental health specialty care on antidepressant length of therapy
    T W Croghan
    Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Med Care 37:AS20-3. 1999
    ..We sought to determine the costs and length of medication treatment consequences of providing mental health specialty care to antidepressant-treated individuals...
  6. ncbi Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy
    R L Obenchain
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Pharmacoeconomics 11:464-72. 1997
    ..We hope that our discussion contributes to a dialogue, leading ultimately to a consensus on analysis of ICERs...
  7. ncbi Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals
    T W Croghan
    Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Adm Policy Ment Health 27:183-95. 2000
    ..Patients initially prescribed fluoxetine were half as likely to be hospitalized as patients initially prescribed TCAs. Once hospitalized, no differential effects of a specific antidepressant on inpatient expenditures were found...